TRAIL-Based Radio-Gene Therapy for Prostate Cancer
Abstract
A recombinant gene was constructed, encoding the soluble form of the human Flt3L gene (hFlex) at the 5' end and the human TRAIL gene at the 3' end. This plasmid (phFlex/TRAIL) was administrated by the hydrodynamic-based gene delivery. As a result, tumor growth was significantly delayed by hFlex/TRAIL plasmid administration. For the expression of GOD, hybrid yeast promoter-containing vector was constructed, confirming the GOD expression. In vivo studies were conducted to examine the effects of intratumoral GOD-IT administration on nude mice. As a result, tumor growth was delayed by GOD-IT administration.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2004
- Accession Number
- ADA425662
Entities
People
- Jae J. Song
Organizations
- University of Pittsburgh